• Je něco špatně v tomto záznamu ?

Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study

K. Dvorak, J. Stritesky, J. Petrtyl, L. Vitek, R. Sroubkova, M. Lenicek, V. Smid, M. Haluzik, R. Bruha,

. 2014 ; 9 (10) : e111551. [pub] 20141028

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010711

Grantová podpora
NT11247 MZ0 CEP - Centrální evidence projektů
NT12290 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of a metabolic syndrome. To date, liver biopsy has been the gold standard used to differentiate between simple steatosis and steatohepatitis/fibrosis. Our aim was to compare the relevance of serum non-invasive parameters and scoring systems in the staging of liver fibrosis and non-alcoholic steatohepatitis (NASH) in patients with NAFLD. METHODS AND FINDINGS: A total of 112 consecutive patients diagnosed with NAFLD were included. A liver biopsy was performed on 56 patients. The Kleiner score was used for the staging and grading of the histology. Non-invasive parameters for fibrosis (hyaluronic acid; AST/ALT; fibrosis scoring indexes OELF, ELF, BARD score, APRI, NAFLD fibrosis score); and inflammation (M30 and M65 cytokeratin-18 fragments) were measured and calculated. The same analyses were performed in 56 patients diagnosed with NAFLD, who were not indicated for liver biopsy. Based on the liver histology, NASH was diagnosed in 38 patients; simple steatosis in 18 patients. A cut-off value of 750 U/L of serum M65 discriminated patients with and without NASH with a 80% sensitivity and 82% specificity (95% CI:57-95). Fibrosis stage F0-F2 was present in 39 patients; F3-F4 in 17 patients. Serum concentrations of hyaluronic acid were higher in patients with advanced fibrosis (p<0.01); a cut-off value of 25 µg/l discriminated patients with F3-F4 with a 90% sensitivity and 84% specificity from those with F0-F2 (95% CI:59-99). When applying the non-invasive criteria to those patients without a liver biopsy, NASH could only be diagnosed in 16%; however, advanced fibrosis could be diagnosed in 35% of them. CONCLUSIONS: In patients with NAFLD, non-invasive serum parameters with a high accuracy can differentiate those patients with NASH and/or advanced fibrosis from those with simple steatosis. A substantial portion of those patients not indicated for liver biopsy might have undiagnosed advanced fibrosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010711
003      
CZ-PrNML
005      
20191107084625.0
007      
ta
008      
160408s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0111551 $2 doi
024    7_
$a 10.1371/journal.pone.0111551 $2 doi
035    __
$a (PubMed)25350286
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dvořák, Karel, $u Charles University in Prague, 1st Faculty of Medicine, 4th Department of Internal Medicine, Prague, Czech Republic. $d 1980- $7 xx0134624
245    10
$a Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study / $c K. Dvorak, J. Stritesky, J. Petrtyl, L. Vitek, R. Sroubkova, M. Lenicek, V. Smid, M. Haluzik, R. Bruha,
520    9_
$a BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of a metabolic syndrome. To date, liver biopsy has been the gold standard used to differentiate between simple steatosis and steatohepatitis/fibrosis. Our aim was to compare the relevance of serum non-invasive parameters and scoring systems in the staging of liver fibrosis and non-alcoholic steatohepatitis (NASH) in patients with NAFLD. METHODS AND FINDINGS: A total of 112 consecutive patients diagnosed with NAFLD were included. A liver biopsy was performed on 56 patients. The Kleiner score was used for the staging and grading of the histology. Non-invasive parameters for fibrosis (hyaluronic acid; AST/ALT; fibrosis scoring indexes OELF, ELF, BARD score, APRI, NAFLD fibrosis score); and inflammation (M30 and M65 cytokeratin-18 fragments) were measured and calculated. The same analyses were performed in 56 patients diagnosed with NAFLD, who were not indicated for liver biopsy. Based on the liver histology, NASH was diagnosed in 38 patients; simple steatosis in 18 patients. A cut-off value of 750 U/L of serum M65 discriminated patients with and without NASH with a 80% sensitivity and 82% specificity (95% CI:57-95). Fibrosis stage F0-F2 was present in 39 patients; F3-F4 in 17 patients. Serum concentrations of hyaluronic acid were higher in patients with advanced fibrosis (p<0.01); a cut-off value of 25 µg/l discriminated patients with F3-F4 with a 90% sensitivity and 84% specificity from those with F0-F2 (95% CI:59-99). When applying the non-invasive criteria to those patients without a liver biopsy, NASH could only be diagnosed in 16%; however, advanced fibrosis could be diagnosed in 35% of them. CONCLUSIONS: In patients with NAFLD, non-invasive serum parameters with a high accuracy can differentiate those patients with NASH and/or advanced fibrosis from those with simple steatosis. A substantial portion of those patients not indicated for liver biopsy might have undiagnosed advanced fibrosis.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a biopsie $7 D001706
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kyselina hyaluronová $x chemie $7 D006820
650    _2
$a zánět $x patologie $7 D007249
650    _2
$a játra $x patologie $7 D008099
650    _2
$a jaterní cirhóza $x patologie $7 D008103
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nealkoholová steatóza jater $x patologie $7 D065626
650    _2
$a prospektivní studie $7 D011446
650    _2
$a ROC křivka $7 D012372
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Stříteský, Jan $u Charles University in Prague, 1st Faculty of Medicine, Department of Pathology, Prague, Czech Republic. $7 xx0096379
700    1_
$a Petrtýl, Jaromír, $u Charles University in Prague, 1st Faculty of Medicine, 4th Department of Internal Medicine, Prague, Czech Republic. $d 1958- $7 xx0089233
700    1_
$a Vítek, Libor, $u Charles University in Prague, 1st Faculty of Medicine, 4th Department of Internal Medicine, Prague, Czech Republic; Charles University in Prague, 1st Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic. $d 1969- $7 xx0035071
700    1_
$a Šroubková, Renata $u Charles University in Prague, 1st Faculty of Medicine, 4th Department of Internal Medicine, Prague, Czech Republic. $7 xx0060522
700    1_
$a Leníček, Martin $u Charles University in Prague, 1st Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic. $7 xx0097551
700    1_
$a Šmíd, Václav $u Charles University in Prague, 1st Faculty of Medicine, 4th Department of Internal Medicine, Prague, Czech Republic. $7 xx0227180
700    1_
$a Haluzík, Martin, $u Charles University in Prague, 1st Faculty of Medicine, 3rd Department of Internal Medicine, Prague, Czech Republic. $d 1970- $7 xx0000707
700    1_
$a Brůha, Radan, $u Charles University in Prague, 1st Faculty of Medicine, 4th Department of Internal Medicine, Prague, Czech Republic. $d 1964- $7 xx0031692
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 10 (2014), s. e111551
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25350286 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20191107084856 $b ABA008
999    __
$a ok $b bmc $g 1114140 $s 935079
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 10 $d e111551 $e 20141028 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NT11247 $p MZ0
GRA    __
$a NT12290 $p MZ0
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...